The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain

Mohammed A. Issa, Sanjeet Narang, Robert N. Jamison, Edward Michna, Robert R. Edwards, David M. Penetar, Ajay D. Wasan

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Many cannabinoid medications are approved in North America or in phase III trials, such as dronabinol, nabilone, or nabiximols. Little is known about their subjective psychoactive effects when used for pain management. We hypothesized that when used for pain, dronabinol has psychoactive effects in a dose-response relationship, whose peak effects are comparable with smoking marijuana. METHODS: This was a randomized controlled trial of single dose placebo, 10 or 20 mg dronabinol in 30 chronic noncancer pain patients taking opioids and not using marijuana. Participants completed the Addiction Research Center Inventory (ARCI) hourly for 8 hours during 3 monitored sessions. Comparison sample was the ARCI ratings in participants with no pain (N=20), monitored every 30 minutes after smoking a 1.99% THC (low) and a 3.51% (high strength) marijuana cigarette. RESULTS: The 10 and 20 mg dronabinol doses had significantly elevated scores over time on 4/5 subscales versus placebo (P

Original languageEnglish (US)
Pages (from-to)472-478
Number of pages7
JournalClinical Journal of Pain
Volume30
Issue number6
DOIs
StatePublished - 2014
Externally publishedYes

Keywords

  • Abuse potential
  • Addiction
  • Cannabinoid
  • Dronabinol
  • Marijuana

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology
  • Medicine(all)

Fingerprint Dive into the research topics of 'The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain'. Together they form a unique fingerprint.

  • Cite this

    Issa, M. A., Narang, S., Jamison, R. N., Michna, E., Edwards, R. R., Penetar, D. M., & Wasan, A. D. (2014). The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain. Clinical Journal of Pain, 30(6), 472-478. https://doi.org/10.1097/AJP.0000000000000022